Back to Search Start Over

Chemokine (C-C motif) ligand 2 gene ablation protects low-density lipoprotein and paraoxonase-1 double deficient mice from liver injury, oxidative stress and inflammation.

Authors :
Luciano-Mateo, Fedra
Cabré, Noemí
Fernández-Arroyo, Salvador
Baiges-Gaya, Gerard
Hernández-Aguilera, Anna
Rodríguez-Tomàs, Elisabet
Mercado-Gómez, Maria
Menendez, Javier A.
Camps, Jordi
Joven, Jorge
Source :
BBA: Molecular Basis of Disease. Jun2019, Vol. 1865 Issue 6, p1555-1566. 12p.
Publication Year :
2019

Abstract

The risk of non-alcoholic fatty liver disease increases with obesity. Vulnerability to oxidative stress and/or inflammation represents a crucial step in non-alcoholic fatty liver disease progression through abnormal metabolic responses. In this study, we investigated the role of CCL2 gene ablation in mice that were double deficient in low density lipoprotein receptor and in paraoxonase-1. Mass spectrometry methods were used to assess the liver metabolic response in mice fed either regular chow or a high-fat diet. Dietary fat caused liver steatosis, oxidative stress and the accumulation of pro-inflammatory macrophages in the livers of double deficient mice. We observed alterations in energy metabolism-related pathways and in metabolites associated with the methionine cycle and the glutathione reduction pathway. This metabolic response was associated with impaired autophagy. Conversely, when we established CCL2 deficiency, histologic features of fatty liver disease were abrogated, hepatic liver oxidative stress decreased, and anti-inflammatory macrophage marker expression levels increased. These changes were associated with the normalization of metabolic disturbances and increased lysosome-associated membrane protein 2, expression, which suggests enhanced chaperone-mediated autophagy. This study demonstrates that CCL2 is a key molecule for the development of metabolic and histological alterations in the liver of mice sensitive to the development of hyperlipidemia and hepatic steatosis, a finding with potential to identify new therapeutic targets in liver diseases. • CCL2 deficiency modulates metabolic alterations associated with PON1. • CCL2 influences liver steatosis and regulate macrophage distribution in mice. • CCL2 controls energy metabolism, methionine cycle and the transsulfuration pathway. • CCL2 alters autophagy and lysosomal function. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09254439
Volume :
1865
Issue :
6
Database :
Academic Search Index
Journal :
BBA: Molecular Basis of Disease
Publication Type :
Academic Journal
Accession number :
136202197
Full Text :
https://doi.org/10.1016/j.bbadis.2019.03.006